Reviewer's report

Title: A Prader-Willi Syndrome Patient with Excessive Daytime Sleepiness and Narcoleptic Symptoms: A Case Report

Version: 2 Date: 28 January 2014

Reviewer: Danny Camfferman

Which of the following best describes what type of case report this is?: Other

If other, please specify:

This Case Report depicts a longitudinal perspective of sleep abnormalities in a female child with Prader-Willi Syndrome, from age 2 to age 9, and the outcome of treating her with a wakefulness promoting agent called Modafinil. The Case Report also notes that the girl was given growth hormone at the age of 8 years and 8 months.

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: Yes

Is this case worth reporting?: Yes

Is the case report persuasive?: Yes

Does the case report have explanatory value?: Yes

Does the case report have diagnostic value?: No

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

Comments to authors:

Missing Information:

Although the case report gives an overall idea about the clinical features and treatment issues of the patient; it lacks some important features in regards to the
history of the child:

• Any history of Allergy of the child.
• Immunization history.

This case report also shows improvement of symptoms (persistent hypersomnia and narcoleptic symptoms) after long term treatment with Modafinil; but might include some common adverse effects of this medication.

• Fever, sore throat, headache, and vomiting with a severe blistering, peeling, and red skin rash
• Bruising, bleeding, tingling, numbness, pain, muscle weakness
• White patches or sores inside your mouth or on your lips
• Hallucinations, unusual thoughts etc.

Modafinil has been reported to be associated with some notifiable side effects. From the date of initial marketing, December 1998, to January 30, 2007, FDA had received six cases of severe cutaneous adverse reactions associated with Modafinil, including Erythema Multiforme (EM), SJS (Steven Johnson’s Syndrome), TEN (Toxic Epidermal Necrolysis), and DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) involving adult and paediatric patients. The FDA issued a relevant alert. In the same alert, the FDA also noted that angioedema and multi-organ hypersensitivity reactions have also been reported in post marketing experience.

Furthermore, Growth Hormone which was started on the patient at the age of 8 years and 8 months, has some beneficial effect which could be mentioned. As some research shows that Growth hormone is important to a patient with Prader-Willi Syndrome because of the following reasons:

• Increased height and growth rate.
• Increase of hand and foot sizes to normal proportions.
• Decrease in body fat.
• Decrease in body mass index (BMI).
• Increase in muscle development.
• Improved respiratory function.
• Improved physical performance.
• Increase in resting energy expenditure (REE).
• Improvement in cholesterol levels.
• Increase in bone mineral density (BMD).

Quality of written English: Acceptable

Declaration of competing interests:
I declare that I have no competing interests.